facebookrssdk flag

RESEARCH

NIKKB RESEARCH UNIT

Towards 2022, NIKKB research will focus on developing customised treatment for the individual patient, research into how we can implement new knowledge in daily practice and understand the lifelong trajectory of musculoskeletal disease.

Focus

NIKKB'S RESEARCH STRATEGY 2018-2022

The Research Unit at NIKKB has formulated a strategy outlining the institute's research priorities for the period 2018-2022.

Download it here

An examination of data from a number of publications demonstrates a slight increase in the risk of cardiovascular problems by the use of high doses of ibuprofen, writes Dagens Medicin on its website dagensmedicin.dk.

 

Ibuprofen is a pain reliever and anti-inflammatory drug, which is given to patients with joint pain among others, but according to a review of available data by the European Medicines Agency (EMA) adverse effects committee PRAC, a dose of 2400 mg or more per day may increase the risk of cardiovascular problems such as heart attack and stroke.

 

PRAC recommends that the advice on the use of high-dose ibuprofen is updated and included in revised form in the product information, to minimize the risk of cardiovascular problems. Especially patients with serious underlying heart or circulatory or patients who have had heart attacks or a stroke are at risk.

 

In addition, PRAC reccomends that physicians carefully evaluate risk factors for heart or circulatory diseases such as smoking, high blood pressure, diabetes and high cholesterol, before initiating treatment with ibuprofen, especially treatment with high doses.

 

PRAC's recommendations also apply to dexibuprofen, but here a dose of 1200 mg or more per day is considered a high dose.

 

Read the article here: http://www.dagensmedicin.dk/nyheder/hjerte-kar/bivirkningskomite-advarer-mod-hojdosis-ibuprofen/?utm_source=apsis&utm_medium=email&utm_campaign=2015-04-21-D